证券代码：603392 证券简称：万泰生物 公告编号：2025-069 北京万泰生物药业股份有限公司 关于重组三价轮状病毒亚单位疫苗（大肠埃希菌） 临床试验申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司（以下简称"公司"）全资子公司厦门 万泰沧海生物技术有限公司收到国家药品监督管理局（以下简称"国家药监局"） 行政许可文书《受理通知书》，公司申报的"重组三价轮状病毒亚单位疫苗（大肠 埃希菌）"临床试验申请已获得受理。现将相关情况公告如下： 一、药品基本信息 产品名称：重组三价轮状病毒亚单位疫苗（大肠埃希菌） 申请事项：境内生产药品注册临床试验 受理号：CXSL2501136 适应症：适用于预防轮状病毒胃肠炎 此次重组三价轮状病毒亚单位疫苗（大肠埃希菌）临床试验申请的受理，是 公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台 的重组蛋白疫苗研发战略又取得关键进展，若该产品研发未来成功上市，将有利 于丰富公司产品布局，进一步提高公司市场竞争力。 截至 2 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-068 北京万泰生物药业股份有限公司 关于 HIV 抗体口腔黏膜渗出液自我检测试剂 取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司（以下简称"公司"）自主研发的人 类免疫缺陷病毒（HIV1+2 型）抗体口腔黏膜渗出液检测试剂盒（胶体金法）取 得国家药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试 剂）》。现将相关信息公告如下： 一、注册证主要信息 注册人住所：北京市昌平区科学园路 31 号 产品名称：人类免疫缺陷病毒（HIV1+2 型）抗体口腔黏膜渗出液检测试剂 盒（胶体金法） 包装规格：1 人份/盒，10 人份/盒，50 人份/盒。 预期用途：用于体外定性检测人口腔黏膜渗出液中的人类免疫缺陷病毒 （HIV1+2 型）抗体，可用于消费者自测。 二、产品其他信息 该产品是国内首个获批的用于自测口腔黏膜渗出液中的人类免疫缺陷病毒 （HIV1+2 型）抗体的试剂盒，这是公司继人类免疫缺陷病毒 1 ...

Core Viewpoint - Wantai Biological Pharmacy (603392.SH) has received acceptance for its clinical trial application for the "Recombinant Trivalent Rotavirus Subunit Vaccine (E. coli)" from the National Medical Products Administration, marking a significant step in the company's innovative vaccine development process [1] Group 1 - The acceptance of the clinical trial application is a crucial advancement in the company's recombinant protein vaccine development strategy based on its proprietary E. coli technology platform [1] - Successful future commercialization of this product could enhance the company's product portfolio and further improve its market competitiveness [1]

Core Viewpoint - Wante Bio (603392.SH) has received approval from the National Medical Products Administration for its self-developed HIV1+2 antibody oral mucosal exudate test kit, marking a significant advancement in self-testing for HIV in China [1] Group 1: Product Approval - The product is the first of its kind in China approved for self-testing of HIV1+2 antibodies in oral mucosal exudate [1] - This approval follows the company's previous successful launches of HIV1 urine antibody test kits and HIV1+2 antibody test kits, showcasing its continuous innovation in the field [1] Group 2: Market Position - The approval reinforces the company's leading technological position and innovative capabilities in the self-testing domain for HIV [1]

Core Viewpoint - Wanta Biotechnology (603392.SH) has received acceptance for its clinical trial application for the "Recombinant Trivalent Rotavirus Subunit Vaccine (E. coli)" from the National Medical Products Administration, marking a significant step in the company's vaccine development process [1] Group 1 - The acceptance of the clinical trial application is a crucial advancement in the company's innovative vaccine research and development [1] - This development signifies a key progress in the company's recombinant protein vaccine research strategy based on its proprietary E. coli technology platform [1] - Successful future commercialization of this product could enhance the company's product portfolio and further improve its market competitiveness [1]

北京万泰生物药业股份有限公司（以下简称"公司"）于2025年10月15日召开第六届董事会第十次会议、 第六届监事会第十次会议，并于2025年10月31日召开2025年第一次临时股东会，审议并通过了《关于变 更部分回购股份用途并注销的议案》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 统一社会信用代码：91110114600067778R 类型：其他股份有限公司（上市） 登录新浪财经APP 搜索【信披】查看更多考评等级 公司因回购专用证券账户中已回购但尚未使用的729,970股股份用途由"用于员工持股计划或股权激 励"变更为"用于注销并减少注册资本"。本次变更部分回购股份用途后，公司回购专用证券账户中的 729,970股已于2025年12月17日在中国证券登记结算有限责任公司完成注销。注销完成后公司总股本由 1,265,122,774股减少至1,264,392,804股，注册资本由1,265,122,774元减少至1,264,392,804元。具体内容详 见公司于2025年12月17日在指定信息披露媒体披露的《北京万泰生物 ...

证券日报网讯 12月23日晚间，万泰生物发布公告称，公司回购专用证券账户中的729，970股已于2025 年12月17日在中国证券登记结算有限责任公司完成注销。注销完成后公司总股本由1，265，122，774股 减少至1，264，392，804股，注册资本由1，265，122，774元减少至1，264，392，804元。近日，公司 完成了工商变更登记手续，并取得了北京市昌平区市场监督管理局换发的《营业执照》。 （编辑 袁冠琳） ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-067 公司因回购专用证券账户中已回购但尚未使用的729,970股股份用途由"用 于员工持股计划或股权激励"变更为"用于注销并减少注册资本"。本次变更部 分回购股份用途后，公司回购专用证券账户中的729,970股已于2025年12月17日 在中国证券登记结算有限责任公司完成注销。注销完成后公司总股本由 1,265,122,774股减少至1,264,392,804股，注册资本由1,265,122,774元减少至 1,264,392,804元。具体内容详见公司于2025年12月17日在指定信息披露媒体披露 的《北京万泰生物药业股份有限公司关于实施回购股份注销暨股份变动的公告》 （公告编号：2025-064）。 近日，公司完成了工商变更登记手续，并取得了北京市昌平区市场监督管理 局换发的《营业执照》，相关信息如下： 公司名称：北京万泰生物药业股份有限公司 统一社会信用代码：91110114600067778R 类型：其他股份有限公司（上市） 住所：北京市昌平区科学园路 31 号 法定代表人：邱子欣 注册资本：126439.2804 万元 北京万泰生物药 ...

万泰生物公告称，公司于2025年10月通过变更部分回购股份用途并注销议案，已回购但未使用的 729,970股股份由"用于员工持股计划或股权激励"变更为"用于注销并减少注册资本"，并于12月17日完 成注销。注销后总股本由1,265,122,774股减至1,264,392,804股，注册资本由1,265,122,774元减至 1,264,392,804元。近日，公司已完成工商变更登记，取得换发的《营业执照》，注册资本现为 126439.2804万元。 ...

Group 1 - Xusheng Group's actual controller has changed to the Guangzhou Municipal Government, with stock resuming trading on December 23, 2025 [1] - Lingyun Light plans to invest up to $5 million in the IPO of Zhipu Hong Kong as a cornerstone investor [1] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuan Robotics to enhance collaboration in the development of dexterous hands [2] Group 2 - Hualian Holdings intends to acquire 100% of the Canadian company Argentum Lithium S.A. for $175 million, which is approximately 1.235 billion yuan [3] - Shiyuan Zhaoye plans to raise no more than 550 million yuan through a convertible bond issuance for the Zhuhai Shiyuan Jingguan Garden project [4] - ST Quanwei and its subsidiary are involved in a civil mediation agreement involving 69.0158 million yuan [4] Group 3 - Jiao Jian Co.'s actual controller has been subjected to criminal coercive measures, but the company's control has not changed [5] - Tianji Technology is facing a lawsuit for alleged collusion in bidding, but its operations remain normal [5] - Jinpan Technology plans to issue 1.672 billion yuan in convertible bonds for data center power modules and other projects [5] Group 4 - Hongqi Chain's shareholder Yonghui Supermarket plans to reduce its stake by up to 3% [6] - Shuangqiang Technology's director did not implement a planned share reduction [7] - Zhuoran Co.'s subsidiary has signed a significant order worth 4.033 billion yuan [8] Group 5 - ST Zhitong's stock will have its risk warning lifted on December 24, 2025, with a change in trading limits [9] - Yingwei Co. plans to reduce its stake by up to 0.56% [10] - Huaxia Happiness's board rejected five temporary proposals from China Ping An Life Insurance [11] Group 6 - China Nonferrous Metals plans to acquire 99.9% of Raura Company for $106 million [11] - Sanhua Intelligent Control expects a net profit of 3.874 billion to 4.649 billion yuan for 2025, a year-on-year increase of 25% to 50% [11] - Chaoxun Communication received a government subsidy of 18.0455 million yuan [12] Group 7 - Jiangfeng Electronics plans to transfer 4% of Shanghai Runping's equity for 60 million yuan [12] - Dingyang Technology has launched a 20 GHz high-bandwidth digital oscilloscope [13] - Linyi Intelligent plans to acquire 35% of Dongguan Liminda Electronics for 875 million yuan [14] Group 8 - Trina Solar has sold its U.S. 5GW module factory to T1, receiving $100 million in cash and shares [14] - Aihua Packaging's major shareholder reduced its stake by 700,000 shares during the stock's abnormal fluctuation period [14] - China Merchants Bank has approved a comprehensive credit limit of 165 billion yuan for China Merchants Group [15] Group 9 - Lingwei Technology plans to acquire 70% of Jiangsu Huimai for 50.2 million yuan [16] - Yongding Co. is increasing its capital by 600 million yuan for its polysilicon subsidiary [19] - Zhong'an Technology's subsidiary is voluntarily extending its share lock-up period by six months [19] Group 10 - Xiangyu Medical's brain-computer interface products have entered over 500 top-tier hospitals, with a target of 700 by the Spring Festival [18] - Wenda Technology's major shareholder has terminated its share reduction plan [18] - Wenta Technology's major shareholder reduced its stake by 1.2097 million shares [18]